227 related articles for article (PubMed ID: 14754454)
1. 3D QSAR models of interactions between beta-tubulin and microtubule stabilizing antimitotic agents (MSAA): a survey on taxanes and epothilones.
Manetti F; Maccari L; Corelli F; Botta M
Curr Top Med Chem; 2004; 4(2):203-17. PubMed ID: 14754454
[TBL] [Abstract][Full Text] [Related]
2. 3D QSAR studies of the interaction between beta-tubulin and microtubule stabilizing antimitotic agents (MSAA). A combined pharmacophore generation and pseudoreceptor modeling approach applied to taxanes and epothilones.
Manetti F; Forli S; Maccari L; Corelli F; Botta M
Farmaco; 2003 May; 58(5):357-61. PubMed ID: 12729829
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of novel epothilone analogues by means of a common pharmacophore and a QSAR pseudoreceptor model for taxanes and epothilones.
Forli S; Manetti F; Altmann KH; Botta M
ChemMedChem; 2010 Jan; 5(1):35-40. PubMed ID: 19904799
[No Abstract] [Full Text] [Related]
4. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
[TBL] [Abstract][Full Text] [Related]
5. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
Giannakakou P; Gussio R; Nogales E; Downing KH; Zaharevitz D; Bollbuck B; Poy G; Sackett D; Nicolaou KC; Fojo T
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2904-9. PubMed ID: 10688884
[TBL] [Abstract][Full Text] [Related]
6. Tubulin interacting agents: novel taxanes and epothilones.
Agrawal NR; Ganapathi R; Mekhail T
Curr Oncol Rep; 2003 Mar; 5(2):89-98. PubMed ID: 12583825
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Fojo T; Menefee M
Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
[TBL] [Abstract][Full Text] [Related]
8. 3D QSAR studies for the beta-tubulin binding site of microtubule-stabilizing anticancer agents (MSAAs): a pseudoreceptor model for taxanes based on the experimental structure of tubulin.
Maccari L; Manetti F; Corelli F; Botta M
Farmaco; 2003 Sep; 58(9):659-68. PubMed ID: 13679158
[TBL] [Abstract][Full Text] [Related]
9. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
[TBL] [Abstract][Full Text] [Related]
10. Understanding tubulin/microtubule-taxane interactions: a quantitative structure-activity relationship study.
Hansch C; Verma RP
Mol Pharm; 2008; 5(1):151-61. PubMed ID: 18171015
[TBL] [Abstract][Full Text] [Related]
11. Epothilone B and its analogs - a new family of anticancer agents.
Altmann KH
Mini Rev Med Chem; 2003 Mar; 3(2):149-58. PubMed ID: 12570848
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the structures of taxane derivatives and their microtubule polymerization activity.
Hidaka M; Koga T; Kiyota H; Horiguchi T; Shi QW; Hirose K; Uchida T
Biosci Biotechnol Biochem; 2012; 76(2):349-52. PubMed ID: 22313785
[TBL] [Abstract][Full Text] [Related]
13. Novel drugs targeting microtubules: the role of epothilones.
Ferrandina G; Mariani M; Andreoli M; Shahabi S; Scambia G; Ferlini C
Curr Pharm Des; 2012; 18(19):2793-803. PubMed ID: 22390763
[TBL] [Abstract][Full Text] [Related]
14. Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system.
Canta A; Chiorazzi A; Cavaletti G
Curr Med Chem; 2009; 16(11):1315-24. PubMed ID: 19355888
[TBL] [Abstract][Full Text] [Related]
15. The biology and medicinal chemistry of epothilones.
Wartmann M; Altmann KH
Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):123-48. PubMed ID: 12678754
[TBL] [Abstract][Full Text] [Related]
16. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity.
Hood KA; West LM; Rouwé B; Northcote PT; Berridge MV; Wakefield SJ; Miller JH
Cancer Res; 2002 Jun; 62(12):3356-60. PubMed ID: 12067973
[TBL] [Abstract][Full Text] [Related]
17. Microtubules: an overview.
Wade RH
Methods Mol Med; 2007; 137():1-16. PubMed ID: 18085218
[TBL] [Abstract][Full Text] [Related]
18. Site occupancy calibration of taxane pharmacology in live cells and tissues.
Pineda JJ; Miller MA; Song Y; Kuhn H; Mikula H; Tallapragada N; Weissleder R; Mitchison TJ
Proc Natl Acad Sci U S A; 2018 Nov; 115(48):E11406-E11414. PubMed ID: 30429313
[TBL] [Abstract][Full Text] [Related]
19. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
20. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
